secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000012208-23-000062
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q2 net loss $1.16B on investment swings; lowers FY2023 outlook on softer biopharma demand
--------------------------------------------------------------------------------

- Net sales $681.1M, down 1.4% (0.3% currency-neutral); ex-COVID revenue up 4.6% currency-neutral.
- Life Science segment sales $300.2M (-6.9%); ex-COVID growth 4.5% driven by ddPCR/qPCR.
- Clinical Diagnostics sales $380.1M (+3.3%); ex-COVID growth 4.8% on diagnostic systems and quality control.
- Operating income $89.6M vs $122.9M; net loss $1,162.3M ($39.59/sh) primarily from Sartorius AG fair value changes.
- CEO lowers FY2023 expectations due to softer demand from large biopharma and persistent early-stage biotech weakness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/0000012208-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/bio-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000012208-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer